 Eric Rosenbaum
Concepts (126)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 5 | 2024 | 744 | 0.720 |
Why?
| | Amoxicillin | 1 | 2020 | 20 | 0.700 |
Why?
| | Blood Transfusion | 3 | 2017 | 127 | 0.670 |
Why?
| | Ureteral Obstruction | 1 | 2020 | 61 | 0.660 |
Why?
| | Cell Separation | 3 | 2013 | 89 | 0.600 |
Why?
| | Blood Platelets | 2 | 2017 | 252 | 0.580 |
Why?
| | Bacteremia | 3 | 2022 | 89 | 0.550 |
Why?
| | Flow Cytometry | 2 | 2016 | 475 | 0.540 |
Why?
| | Acute Kidney Injury | 1 | 2020 | 291 | 0.530 |
Why?
| | Antibodies | 1 | 2016 | 151 | 0.530 |
Why?
| | Bone Marrow Transplantation | 1 | 2016 | 112 | 0.530 |
Why?
| | Antigens, CD34 | 2 | 2013 | 65 | 0.500 |
Why?
| | Ehrlichia | 1 | 2014 | 6 | 0.480 |
Why?
| | Ehrlichiosis | 1 | 2014 | 14 | 0.470 |
Why?
| | Optic Neuritis | 1 | 2013 | 21 | 0.440 |
Why?
| | Malaria, Falciparum | 1 | 2013 | 14 | 0.440 |
Why?
| | Osteomyelitis | 1 | 2014 | 125 | 0.420 |
Why?
| | Leukapheresis | 1 | 2012 | 15 | 0.400 |
Why?
| | Anti-Infective Agents | 2 | 2022 | 95 | 0.370 |
Why?
| | Endophthalmitis | 2 | 2021 | 24 | 0.300 |
Why?
| | Acinetobacter Infections | 1 | 2024 | 8 | 0.230 |
Why?
| | Carbapenems | 1 | 2024 | 16 | 0.230 |
Why?
| | Acinetobacter baumannii | 1 | 2024 | 12 | 0.230 |
Why?
| | Cephalosporins | 1 | 2024 | 38 | 0.230 |
Why?
| | Microbial Sensitivity Tests | 1 | 2024 | 272 | 0.210 |
Why?
| | Humans | 20 | 2024 | 50201 | 0.210 |
Why?
| | Pharyngitis | 1 | 2022 | 16 | 0.210 |
Why?
| | Gram-Negative Bacterial Infections | 1 | 2022 | 42 | 0.200 |
Why?
| | Streptococcal Infections | 1 | 2022 | 46 | 0.200 |
Why?
| | Chorioretinitis | 1 | 2021 | 9 | 0.190 |
Why?
| | Fungemia | 1 | 2021 | 37 | 0.180 |
Why?
| | Phenylketonurias | 1 | 2020 | 11 | 0.180 |
Why?
| | Eye Infections, Fungal | 1 | 2021 | 19 | 0.180 |
Why?
| | Leprosy, Multibacillary | 1 | 2020 | 5 | 0.180 |
Why?
| | Armadillos | 1 | 2020 | 6 | 0.180 |
Why?
| | Candidiasis | 1 | 2021 | 114 | 0.170 |
Why?
| | Crystallization | 1 | 2020 | 31 | 0.170 |
Why?
| | Phenylalanine | 1 | 2020 | 131 | 0.170 |
Why?
| | Male | 11 | 2024 | 25572 | 0.150 |
Why?
| | Babesiosis | 1 | 2017 | 6 | 0.140 |
Why?
| | Blood Grouping and Crossmatching | 1 | 2017 | 5 | 0.140 |
Why?
| | Cytotoxicity Tests, Immunologic | 1 | 2016 | 27 | 0.140 |
Why?
| | Hematopoietic Stem Cell Mobilization | 2 | 2013 | 56 | 0.140 |
Why?
| | Transplantation, Homologous | 1 | 2016 | 140 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2020 | 1041 | 0.130 |
Why?
| | Bacillaceae | 1 | 2015 | 4 | 0.120 |
Why?
| | Ichthyosis, Lamellar | 1 | 2015 | 5 | 0.120 |
Why?
| | Eye Injuries, Penetrating | 1 | 2015 | 12 | 0.120 |
Why?
| | Granulocytes | 1 | 2014 | 26 | 0.120 |
Why?
| | Blood | 1 | 2014 | 27 | 0.120 |
Why?
| | Factor VIII | 1 | 2014 | 23 | 0.120 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2014 | 15 | 0.120 |
Why?
| | ADAM Proteins | 1 | 2014 | 20 | 0.120 |
Why?
| | Anesthesia, Obstetrical | 1 | 2015 | 39 | 0.120 |
Why?
| | Plasma Exchange | 1 | 2014 | 23 | 0.120 |
Why?
| | Microscopy | 1 | 2014 | 59 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2014 | 187 | 0.110 |
Why?
| | Antimalarials | 1 | 2013 | 24 | 0.110 |
Why?
| | Aged | 6 | 2020 | 9505 | 0.110 |
Why?
| | Platelet Count | 1 | 2013 | 74 | 0.110 |
Why?
| | Polymerase Chain Reaction | 1 | 2014 | 456 | 0.110 |
Why?
| | Female | 8 | 2020 | 26829 | 0.110 |
Why?
| | Myelodysplastic Syndromes | 1 | 2013 | 79 | 0.100 |
Why?
| | Stem Cell Transplantation | 1 | 2013 | 179 | 0.100 |
Why?
| | Bone Marrow | 1 | 2014 | 356 | 0.100 |
Why?
| | Blood Component Removal | 1 | 2012 | 10 | 0.100 |
Why?
| | Hematopoietic Stem Cells | 1 | 2013 | 182 | 0.100 |
Why?
| | Infant | 1 | 2020 | 3584 | 0.100 |
Why?
| | Multiple Myeloma | 3 | 2017 | 2934 | 0.090 |
Why?
| | Adult | 6 | 2021 | 13486 | 0.090 |
Why?
| | Pregnancy Complications | 1 | 2015 | 381 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2021 | 6190 | 0.080 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2013 | 556 | 0.080 |
Why?
| | Aged, 80 and over | 3 | 2020 | 3158 | 0.060 |
Why?
| | Sulbactam | 1 | 2024 | 5 | 0.060 |
Why?
| | Azabicyclo Compounds | 1 | 2024 | 11 | 0.060 |
Why?
| | Bacterial Outer Membrane Proteins | 1 | 2024 | 21 | 0.060 |
Why?
| | Middle Aged | 5 | 2020 | 12356 | 0.060 |
Why?
| | DNA Transposable Elements | 1 | 2024 | 105 | 0.060 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2024 | 64 | 0.060 |
Why?
| | Receptors, Cell Surface | 1 | 2024 | 120 | 0.050 |
Why?
| | Arkansas | 2 | 2020 | 1988 | 0.050 |
Why?
| | Treatment Outcome | 1 | 2013 | 5203 | 0.050 |
Why?
| | Streptococcus pyogenes | 1 | 2022 | 18 | 0.050 |
Why?
| | Staphylococcus | 1 | 2021 | 35 | 0.050 |
Why?
| | Fundus Oculi | 1 | 2021 | 25 | 0.050 |
Why?
| | Proline | 1 | 2020 | 30 | 0.050 |
Why?
| | Mycobacterium leprae | 1 | 2020 | 8 | 0.050 |
Why?
| | Soil Microbiology | 1 | 2020 | 19 | 0.050 |
Why?
| | Tyrosine | 1 | 2020 | 95 | 0.040 |
Why?
| | Benchmarking | 1 | 2020 | 61 | 0.040 |
Why?
| | Infant, Newborn | 2 | 2020 | 2770 | 0.040 |
Why?
| | Valine | 1 | 2020 | 57 | 0.040 |
Why?
| | Citrulline | 1 | 2020 | 100 | 0.040 |
Why?
| | Methionine | 1 | 2020 | 134 | 0.040 |
Why?
| | Arginine | 1 | 2020 | 185 | 0.040 |
Why?
| | Biopsy | 1 | 2020 | 592 | 0.040 |
Why?
| | Incidence | 1 | 2021 | 1000 | 0.040 |
Why?
| | Quinine | 1 | 2017 | 5 | 0.040 |
Why?
| | Babesia | 1 | 2017 | 5 | 0.040 |
Why?
| | Clindamycin | 1 | 2017 | 13 | 0.040 |
Why?
| | Platelet Transfusion | 1 | 2017 | 28 | 0.040 |
Why?
| | Skin | 1 | 2020 | 416 | 0.040 |
Why?
| | Doxycycline | 1 | 2017 | 33 | 0.040 |
Why?
| | Lymphoma, Follicular | 1 | 2017 | 27 | 0.040 |
Why?
| | Histocompatibility Antigens Class I | 1 | 2017 | 44 | 0.040 |
Why?
| | Fatal Outcome | 1 | 2017 | 195 | 0.030 |
Why?
| | Diet | 1 | 2020 | 554 | 0.030 |
Why?
| | Fibrosis | 1 | 2017 | 178 | 0.030 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 104 | 0.030 |
Why?
| | Eye Foreign Bodies | 1 | 2015 | 6 | 0.030 |
Why?
| | Young Adult | 2 | 2015 | 4052 | 0.030 |
Why?
| | Pregnancy, High-Risk | 1 | 2015 | 60 | 0.030 |
Why?
| | Autoantibodies | 1 | 2014 | 114 | 0.030 |
Why?
| | Cesarean Section | 1 | 2015 | 185 | 0.030 |
Why?
| | Pregnancy Outcome | 1 | 2015 | 237 | 0.030 |
Why?
| | Immunosuppressive Agents | 1 | 2014 | 226 | 0.030 |
Why?
| | Risk Factors | 1 | 2021 | 3644 | 0.030 |
Why?
| | Risk | 1 | 2013 | 315 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2014 | 639 | 0.030 |
Why?
| | Child, Preschool | 1 | 2020 | 3896 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2013 | 463 | 0.020 |
Why?
| | Child | 1 | 2020 | 6862 | 0.020 |
Why?
| | Pregnancy | 1 | 2015 | 2609 | 0.020 |
Why?
| | United States | 1 | 2017 | 4898 | 0.020 |
Why?
| | Animals | 1 | 2020 | 13141 | 0.020 |
Why?
|
|
Rosenbaum's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|